These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29360622)

  • 21. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
    Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
    Mrózek K; Kohlschmidt J; Blachly JS; Nicolet D; Carroll AJ; Archer KJ; Mims AS; Larkin KT; Orwick S; Oakes CC; Kolitz JE; Powell BL; Blum WG; Marcucci G; Baer MR; Uy GL; Stock W; Byrd JC; Eisfeld AK
    Leukemia; 2023 Apr; 37(4):788-798. PubMed ID: 36823396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
    Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The incidence and clinical significance of nucleophosmin mutations in childhood AML.
    Brown P; McIntyre E; Rau R; Meshinchi S; Lacayo N; Dahl G; Alonzo TA; Chang M; Arceci RJ; Small D
    Blood; 2007 Aug; 110(3):979-85. PubMed ID: 17440048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.
    Wakita S; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Koizumi M; Fujiwara Y; Yui S; Fukunaga K; Ryotokuji T; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Fukuda T; Inokuchi K
    Leukemia; 2016 Mar; 30(3):545-54. PubMed ID: 26488113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
    Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
    Pastore F; Dufour A; Benthaus T; Metzeler KH; Maharry KS; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Kakadia PM; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Sauerland MC; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Bohlander SK; Marcucci G; Spiekermann K; Bloomfield CD; Hoster E
    J Clin Oncol; 2014 May; 32(15):1586-94. PubMed ID: 24711548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Keren-Froim N; Heering G; Sharvit G; Zlotnik M; Nagler A; Shimoni A; Avigdor A; Canaani J
    Ann Hematol; 2022 Feb; 101(2):309-316. PubMed ID: 34989829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic significance of minimal residual disease before post-remission therapy in younger adult acute myeloid leukemia patients with intermediate risk and negative of FLT3-ITD, NPM1 and biallelic CEBPA mutations].
    Zhang Y; Zhang YM; Zhang YS; Tang GS; Zhang WP; Yang JM; Wang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):597-601. PubMed ID: 32397025
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
    Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
    Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
    Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
    Alpermann T; Schnittger S; Eder C; Dicker F; Meggendorfer M; Kern W; Schmid C; Aul C; Staib P; Wendtner CM; Schmitz N; Haferlach C; Haferlach T
    Haematologica; 2016 Feb; 101(2):e55-8. PubMed ID: 26471486
    [No Abstract]   [Full Text] [Related]  

  • 40. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.